格林-巴利综合征(GBS)的病因可能是自身免疫。大约三分之二的患者通常在常见传染病后5天至3周内出现首发症状,手术,或接种疫苗。感染是超过50%的患者的触发因素。近年来,越来越多的研究表明,一些免疫检查点抑制剂和COVID-19也可能导致GBS的发生。然而,药物被认为是GBS的罕见原因。我们病例中的患者是一名70岁的男性,他在开始使用苏金单抗治疗牛皮癣后出现了GBS。诊断表明苏金单抗与GBS的发展之间存在潜在关联,根据Naranjo药物不良反应(ADR)概率量表,我们决定停药.在这次干预之后,随着免疫球蛋白的管理,患者的肢体无力得到了显着改善。GBS与苏金单抗治疗的关联,正如在这种情况下观察到的,似乎并不常见。可能将苏金单抗与GBS发展联系起来的潜在机制尚未完全理解,需要进一步的科学调查和严格的调查。然而,我们希望这份报告能提高医疗专业人员的认识和警惕性,以提高患者用药的安全性。
The etiology of Guillain-Barré syndrome (GBS) may be autoimmune. About two-thirds of patients typically experience their first symptoms within 5 days to 3 weeks after common infectious diseases, surgery, or vaccination. Infection is a triggering factor for over 50% of patients. In recent years, a growing number of studies have indicated that some immune checkpoint inhibitors and COVID-19 may also contribute to the occurrence of GBS. However, drugs are considered a rare cause of GBS. The patient in our
case was a 70-year-old man who developed GBS after initiating secukinumab for psoriasis. Upon diagnosis suggesting a potential association between secukinumab and the development of GBS, as per the Naranjo adverse drug reaction (ADR) probability scale, we decided to discontinue the drug. Following this intervention, along with the administration of immunoglobulin, the patient exhibited a significant improvement in extremity weakness. The association of GBS with secukinumab treatment, as observed in this
case, appears to be uncommon. The underlying mechanisms that may link secukinumab to the development of GBS are not yet fully understood and warrant further scientific inquiry and rigorous investigation. However, we hope that this report can raise greater awareness and vigilance among medical professionals to enhance the safety of patients\' medication.